Compare Incyte Corporation (INCY) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sunrun Inc — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.85B), while Sunrun Inc trades at $7.62 (market cap $1.83B). The key difference: Incyte Corporation is far larger — about 12.5× Sunrun Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Sunrun Inc for 16 Days on average.
| INCY | RUN | |
|---|---|---|
Market Cap | $22.85B | $1.83B |
Volume | 1,927,029 | 8,672,852 |
Sector | Health | Energy |
52-Week High | $129.93 | $21.41 |
52-Week Low | $83.80 | $7.59 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $18.35B | $16.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Sunrun (RUN) trades at $7.61, down 2.06% amid broader solar sector weakness. The stock shows bearish technical signals with resistance at $8, while fundamentals reveal mixed results: strong valuation metrics (P/E 5.16, P/S 0.59) contrast with negative operating cash flow and high debt levels. Recent positive developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing solutions.
Despite attractive valuations and analyst optimism (62% buy rating, $16.56 target), RUN faces significant headwinds from high borrowing costs impacting solar financing, weak underlying business trends, and persistent cash burn. The stock presents a high-risk opportunity with substantial upside potential if execution improves, but requires careful monitoring of cash flow stabilization and subscriber growth metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
